The division of the pharmaceutical industry has intensified, and the leader of the innovative pharmaceutical industry chain is expected to benefit.

"Pharmaceutical network industry dynamics" At present, with the promotion of national harvesting, provinces and cities are also actively promoting high-value medical supplies centralized belt procurement.
the same time, with the new version of the medical insurance catalog adjustment started, in the banishment of some clinical value is not high, do not have economic and other drugs at the same time, will further encourage the development of pharmaceutical innovation.
A securities research report pointed out that it is optimistic about the dynamic adjustment of health insurance dividends, the supply of innovative drugs to improve, pay tilt, overlay review reform under the local innovative drugs IND (clinical trial declaration of new drugs) continued to reach a new high, is expected to usher in 2023-2026 domestic innovative drugs golden development period.
Against this background, the industry will continue to differentiate, or further promote the development of innovative pharmaceutical industry chain, good related pharmaceutical enterprises, the industry is optimistic about including Hengrui Pharmaceuticals, Pharmaceutical Mingkangde, Meirui Medical and so on.
, "Pharma One Brother" Hengrui Pharmaceutical is in the transition stage from imitation to innovation-driven.
the first half of this year, Hengrui has continued to invest heavily in research and development.
, in the first half of 2020, Hengrui Pharmaceuticals invested 1,863 million yuan in research and development, up 25.56 percent from a year earlier, and its share of sales revenue rose to 16.48 percent.
and Hengrui Pharmaceuticals will fully cost research and development costs.
in high-intensity research and development investment, Hengrui Pharma has basically formed every year innovative drug declaration clinical.
At present, Hengrui Pharmaceutical has a wealth of research and development pipeline, the coverage of adaptive diseases involving anti-tumor, anesthesia and other core areas, but also in the layout of diabetes, cardiovascular diseases, autoimmune diseases and other chronic diseases.
among them, Apatini, thiopental non-gesting (19K), pyridoxine, carelli pearl monoanti (PD-1), Rema lun and other heavy drugs have been on the market.
in the first half of this year, Hengrui Pharmaceuticals obtained 3 batch of innovative pharmaceutical preparations and 1 batch of production of generic pharmaceutical preparations, and 37 clinical batches of innovative pharmaceuticals, completing the consistent evaluation of 3 varieties and the declaration of consistency evaluation of 2 products.
in July, at least eight of the company's drugs received a "Notice of Approval for Clinical Trials of Drugs" issued by the National Drug Administration, and in June, two more drugs received clinical trial notifications.
It is also worth mentioning that Hengrui Pharmaceuticals approved in May 2019 for the treatment of Hodgkin's lymphoma PD-1 Karelli pearl single resistance, but also this year approved liver cancer second-line, esophageal cancer second-line and non-squamous non-small cell lung cancer three major adaptive disorders, in the development of large-adaptive disease progress more than other enterprises.
the first half of 2020, Hengrui Pharmaceuticals achieved revenue of RMB11,309 million, up 12.79% YoY, while net profit attributable to shareholders of listed companies was RMB2.662 billion, up 10.34% YoY.
the company's performance growth in the first half of this year hit Waterloo, the industry generally believes that continued strong investment in research and development may allow its performance to grow further.
drug Mingkangde for the domestic cro field of the entire industrial chain layout of the leading enterprises, and no other competitive competitors.
in the context of a broad policy to encourage biopharmaceutical innovation, CRO will make a big difference, the industry ushered in opportunities.
forecast that the domestic CRO market will reach US$21.4 billion by 2023, with an average growth rate of 29.8% in 2019-2023.
Medical is a leading domestic medical device enterprises, whether in terms of revenue or debt service capacity are outstanding, the current market value has broken 100 billion, with good sustainability.
According to the semi-annual results forecast of Myer Medical, Meirui Medical achieved operating income of RMB98.47-10.667 billion in the first half of 2020, an increase of 20% - 30% over the same period last year, and realized net profit attributable to shareholders of listed companies of RMB326,934.50-350625.40 million, an increase of 38% to 48% over the same period last year.
.